Article
Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
Bioorganic & medicinal chemistry - 15 Jan 2021
Gao Ping, Song Shu, Frutos-Beltrán Estrella, Li Wenxin, Sun Bin, Kang Dongwei, Zou Jinmi, Zhang Jian, Pannecouque Christophe, De Clercq Erik, Menéndez-Arias Luis, Zhan Peng, Liu Xinyong
Abstract excerpt
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used in combination therapies against HIV-1. However, emergent and transmitted drug resistance compromise their efficacy in the clinical setting. Y181C is selected in patients receiving nevirapine, etravirine and rilpivirine, and together with K103N is the most prevalent NNRTI-associated mutation in HIV-infected patients. Herein, we report on the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
